Oesophageal cancer: Current status of multimodality therapy;Ösophaguskarzinom: Aktueller Stand der multimodalen Therapie

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 136, Issue 4, 2011, Pages 312-316

  Vallbohmer D ^a   Schroder W ^a   Brabender, J ^a   Holscher A H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

multimodality treatment; oesophageal cancer; response prediction

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER INVASION; CANCER STAGING; DRUG DELIVERY SYSTEM; ESOPHAGUS TUMOR; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; ESOPHAGEAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052160035     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1271578     Document Type: Article

References (37)

1. Hölscher A H., Vallböhmer D. Surgical treatment of esophageal tumors including local ablation. Zentralbl Chir 2007 132 18-36
2. Lerut T, Moons J, Coosemans W et al. Multidisciplinary treatment of advanced cancer of the esophagus and gastroesophageal junction: a European center's approach. Surg Oncol Clin N Am 2008 17 485-502 (Pubitemid 351672070)
3. Bhansali M S., Vaidya J S., Bhatt R G. et al. Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann Oncol 1996 7 355-359 (Pubitemid 26246786)
4. Urschel J D., Vasan H, Blewett C J. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002 183 274-279 (Pubitemid 34273984)
5. Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003 185 538-543 (Pubitemid 36627845)
6. Kaklamanos I G., Walker G R., Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 2003 10 754-761 (Pubitemid 40486875)
7. Malthaner R, Wong R, Rumble R et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004 2 35-35
8. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Gut 2004 53 925-930 (Pubitemid 38824146)
9. Greer S, Goodney P, Sutton J et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005 137 172-177 (Pubitemid 40174424)
10. Vogt K, Fenlon D, Rhodes S et al. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews 2006 3 CD001556
11. Gebski V, Burmeister B, Smithers B M., et al., Australian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007 8 226-234 (Pubitemid 46291702)
12. Jin H L., Zhu H, Ling T S. et al. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 2009 15 5983-5991
13. Baldus S E., Mönig S P., Schröder W et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 2004 25 421-427 (Pubitemid 40022464)
14. Schneider P M., Baldus S E., Metzger R et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005 242 684-692 (Pubitemid 41567124)
15. Vallböhmer D, Hölscher A H., DeMeester S et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 2010 252 744-749
16. Fok M, McShane J, Law S YK et al. Prospective randomised study in the treatment of oesophageal carcinoma. Asian J Surg 1994 17 223-229 (Pubitemid 24317893)
17. Launois B, Delarue D, Campion J P. et al. Preoperative radiotherapy forcarcinoma of the esophagus. Surg Gynecol Obstet 1981 153 690-692
18. Gignoux M, Roussel A, Paillot B et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987 11 426-432 (Pubitemid 17131689)
19. Wang M, Gu X Z., Yin W et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206patients. Int J Radiat Oncol Biol Phys 1989 16 325-327 (Pubitemid 19077192)
20. Nygaard K, Hagen S, Hansen H S. et al. Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992 16 1104-1109
21. Arnott S J., Duncan W, Kerr G R. et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992 24 108-113
22. Arnott S J., Duncan W, Gignoux M et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005 4 CD001799
23. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2003 4 CD001556
24. Medical Research Council Oesophageal Cancer Working Group. Surgicalresection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002 359 1727-1733
25. Wijnhoven B P., van Lanschot J J., Tilanus H W. et al. Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. World J Surg 2009 33 2606-2614
26. Gaast A V., van Hagen P, Hulshof M et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phaseIII study. J Clin Oncol 2010 28 15s (abstract 4004)
27. Bollschweiler E, Metzger R, Drebber U et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009 20 231-238
28. Ruhstaller T, Pless M, Dietrich D et al. Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter PhaseIB/II Trial (SAKK 75/06). J Clin Oncol 2011 29 626-639
29. Gibson M K., Catalano P J., Kleinberg L et al. E2205: A phaseII study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. J Clin Oncol 2010 28 15s (abstract 4064)
30. Lordick F. Neoadjuvant therapy for squamous cell carcinoma of the esophagus. Chirurg 2005 76 1025-1032 (Pubitemid 41639856)
31. Semrau R, Vallböhmer D, Hölscher A H. et al. Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy. Chirurg 2009 80 1035-1041
32. Ruol A, Rizzetto C, Castoro C et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell cancer of the thoracic esophagus. Ann Surg 2010 252 788-796
33. Bollschweiler E, Besch S, Drebber U et al. Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer. Ann Surg Oncol 2010 17 3187-3194
34. Schneider P M., Metzger R, Schaefer H et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008 248 902-908
35. Lordick F, Ott K, Krause B J. et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phaseII trial. Lancet Oncol 2007 8 797-805 (Pubitemid 47308659)
36. 18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009 250 888-894
37. Vallböhmer D, Brabender J, Metzger R et al. Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors. JGastrointest Surg 2010 23 185-190